Table 3.
Multivariate analysis of relapse, NRM, and survival outcomes.
| Relapse | NRM | OS | DFS | GRFS | CRFS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | ||
| Donor | |||||||||||||
| MSD | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| 8/8MUD | 0.74 (0.56–0.99) | 0.047 | 1.21 (0.86–1.71) | 0.260 | 0.90 (0.71–1.13) | 0.390 | 0.86 (0.69–1.08) | 0.208 | 0.84 (0.69–1.03) | 0.101 | 0.81 (0.67–0.98) | 0.032 | |
| 7/8MUD | 0.74 (0.54–1.01) | 0.064 | 1.38 (0.95–2.01) | 0.083 | 1.00 (0.77–1.29) | 0.960 | 0.94 (0.73–1.20) | 0.622 | 0.93 (0.75–1.15) | 0.539 | 0.88 (0.72–1.09) | 0.256 | |
| UCB | 0.79 (0.58–1.06) | 0.120 | 1.43 (1.01–2.02) | 0.041 | 1.15 (0.91–1.46) | 0.230 | 1.04 (0.82–1.30) | 0.728 | 0.86 (0.70–1.05) | 0.152 | 0.80 (0.65–0.97) | 0.025 | |
| Recipient age | |||||||||||||
| 50–59 years | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| ≥ 60 years | 1.45 (1.18–1.78) | <0.001 | 1.01 (0.82–1.24) | 0.890 | 1.24 (1.07–1.44) | 0.003 | 1.31 (1.14–1.51) | <0.001 | 1.19 (1.04–1.35) | 0.007 | 1.14 (1.01–1.29) | 0.028 | |
| Recipient sex | |||||||||||||
| Female | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| Male | 1.09 (0.89–1.33) | 0.400 | 1.10 (0.89–1.36) | 0.340 | 1.17 (1.01–1.37) | 0.036 | 1.12 (0.96–1.29) | 0.127 | 1.10 (0.96–1.25) | 0.145 | 1.13 (0.99–1.28) | 0.055 | |
| PS | |||||||||||||
| 0–1 | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| 2–4 | 1.67 (1.26–2.22) | <0.001 | 1.21 (0.85–1.72) | 0.270 | 1.84 (1.47–2.32) | <0.001 | 1.74 (1.39–2.18) | <0.001 | 1.55 (1.26–1.91) | <0.001 | 1.43 (1.16–1.76) | <0.001 | |
| HCT–CI | |||||||||||||
| 0–2 | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| ≥3 | 1.02 (0.83–1.24) | 0.850 | 1.30 (1.06–1.60) | 0.011 | 1.32 (1.13–1.53) | <0.001 | 1.22 (1.05–1.41) | 0.006 | 1.09 (0.95–1.24) | 0.192 | 1.11 (0.97–1.26) | 0.104 | |
| Karyotype | |||||||||||||
| Others | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| Poor | 2.33 (1.93–2.81) | <0.001 | 0.89 (0.74–1.07) | 0.240 | 1.64 (1.43–1.89) | <0.001 | 1.67 (1.46–1.90) | <0.001 | 1.39 (1.24–1.57) | <0.001 | 1.45 (1.29–1.62) | <0.001 | |
| Disease risk at HCT | |||||||||||||
| Low-risk | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| High-risk | 1.14 (0.93–1.38) | 0.180 | 0.96 (0.79–1.17) | 0.720 | 1.03 (0.89–1.19) | 0.681 | 1.06 (0.92–1.22) | 0.371 | 1.06 (0.94–1.20) | 0.315 | 1.08 (0.96–1.22) | 0.104 | |
| Conditioning regimen | |||||||||||||
| MAC | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| RIC | 0.82 (0.68–0.99) | 0.041 | 0.89 (0.73–1.08) | 0.250 | 0.76 (0.65–0.87) | <0.001 | 0.80 (0.69–0.91) | 0.001 | 0.77 (0.68–0.87) | <0.001 | 0.76 (0.68–0.86) | <0.001 | |
| GVHD prophylaxis | |||||||||||||
| With MTX | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| Without MTX | 0.69 (0.53–0.90) | 0.008 | 1.07 (0.83–1.37) | 0.580 | 0.84 (0.69–1.02) | 0.079 | 0.82 (0.68–0.98) | 0.033 | 0.93 (0.79–1.09) | 0.386 | 0.96 (0.82–1.13) | 0.658 | |
| Use of ATG | |||||||||||||
| No | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| Yes | 0.96 (0.71–1.30) | 0.830 | 0.72 (0.50–1.02) | 0.069 | 0.75 (0.58–0.97) | 0.031 | 0.82 (0.64–1.04) | 0.109 | 0.67 (0.54–0.83) | <0.001 | 0.76 (0.62–0.93) | 0.008 | |
NRM non-relapse mortality, OS overall survival, DFS disease-free survival, GRFS graft-versus-host disease (GVHD)-free, relapse-free survival, CRFS chronic GVHD-free relapse-free survival, MSD matched sibling donor, MUD matched unrelated donor, UCB unrelated cord blood, PS performance status, HCT-CI hematopoietic cell transplantation-specific comorbidity index, HCT hematopoietic cell transplantation, MAC myeloablative conditioning, RIC reduced-intensity conditioning, GVHD graft-versus-host disease, MTX methotrexate, ATG antithymocyte globulin, HR hazard ratio, CI confidence interval. The P values in bold are statistically significant (<0.05).